PARENTERAL ESMOLOL FORMULATION
A parenteral formulation of esmolol hydrochloride for use in the treatment of a patient suffering from tachycardia comprising a lyophilized powder consisting of pure esmolol hydrochloride, wherein said powder is reconstituted to obtain a ready-to-use i.v. solution of esmolol hydrochloride at a concentration of 20-100 mg/mL, and said i.v. solution is directly administered to the patient, and further a method of producing a ready-to-use i.v. solution of esmolol hydrochloride by reconstituting a lyophilized powder consisting of pure esmolol hydrochloride with a solvent, characterized in that said solvent is an i.v. solvent devoid of alcohol or a buffer excipient, in an amount necessary to obtain a ready-to-use i.v. solution at a concentration of 20-100 mg/mL, and the ready-to-use i.v. solution containing a parenteral formulation of 20-100 mg/mL pure esmolol hydrochloride in an infusion device or consisting of a parenteral formulation of 20-100 mg/mL pure esmolol hydrochloride, WFI and/or saline solution, devoid of any alcohol or buffer excipients.
1 . A method of treating a patient suffering from tachycardia, comprising the steps of:
reconstituting a lyophilized powder consisting of pure esmolol hydrochloride with an aqueous solution to obtain a ready-to-use intravenous (i.v.) solution of esmolol hydrochloride at a concentration of 20-100 mg/mL, wherein the solution is free of alcohol and buffer excipients; and
administering the i.v. solution to the patient.
2 . The method of claim 1 , wherein the solution is selected from the group consisting of water for injection (WFI) and saline solution.
3 . The method of claim 1 , wherein the i.v. solution has a pH of 4.5 to 5.0.
4 . The method of claim 1 , wherein the esmolol hydrochloride concentration is at least 50 mg/mL.
5 . The method of claim 1 , wherein the i.v. solution is administered as a continuous infusion.
6 . The method of claim 1 , wherein the i.v. solution is administered as a maintenance infusion at a dose of at least 25 μg/kg/min.
7 . The method of claim 6 , wherein the i.v. solution is administered following an initial infusion of the i.v. solution at a dose of at least 300 μg/kg/min.
8 . The method of claim 1 , wherein the i.v. solution is local tissue tolerant at the infusion site, thereby preventing local venous irritation or skin necrosis at the infusion site.
9 . The method of claim 1 , wherein the patient is:
a. suffering from a condition selected from the group consisting of supraventricular tachycardia, ventricular tachycardia, non-compensatory sinus tachycardia, atrial fibrillation, and atrial flutter, or
b. in need of blood pressure lowering during aortic dissection or for controlled hypotension to avoid blood loss in ear/nose/throat surgery or for diagnostic purposes.
10 . The method of claim 1 , wherein the patient is experiencing one or more conditions selected from the group consisting of cardiac decompensation, renal decompensation, hypernatremia, hyperchloramic acidosis, and hyperhydratation.
11 . A ready-to-use i.v. solution comprising a parenteral formulation of 20-100 mg/mL pure reconstituted lyophilized esmolol hydrochloride and water for injection (WFI), devoid of any alcohol or buffer excipients.
12 . The ready-to-use i.v. solution of claim 11 , wherein the i.v. solution is a saline solution.
13 . The ready-to-use i.v. solution of claim 11 , wherein the i.v. solution is stored in an infusion device.
14 . A kit for preparing the ready-to-use i.v. solution of claim 11 comprising the following components:
a) a lyophilized powder consisting of pure esmolol hydrochloride, and
b) WFI or saline solution.
15 . The kit of claim 14 , wherein 2500 mg of the powder is contained in a 50 mL vial.
16 . The kit of claim 14 , further comprising an infusion device suitable for i.v. administration.